IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10287251 B1

PDFFull Text
Date of Patent:
May. 14, 2019

Filed:

Jun. 22, 2016

Pyrazole derivative or pharmaceutically acceptable salt thereof

Applicant:

Kissei Pharmaceutical Co., Ltd., Matsumoto-shi, Nagano, JP;

Inventors:

Hideaki Hirasawa, Azumino, JP;

Fumiya Tanada, Azumino, JP;

Yousuke Mutai, Azumino, JP;

Nobuhiko Fushimi, Azumino, JP;

Junichi Kobayashi, Azumino, JP;

Yoshiro Kijima, Azumino, JP;

Assignee:

KISSEI PHARMACEUTICAL CO., LTD., Matsumoto-shi, Nagano, JP;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Laura L Stockton

Int. Cl.
CPC ...
C07D 231/12 (2006.01); C07D 401/14 (2006.01); C07D 491/052 (2006.01); C07D 417/12 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); A61K 31/436 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/4178 (2006.01); A61K 31/4192 (2006.01); A61K 31/4196 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); A61P 13/10 (2006.01);
U.S. Cl.
CPC ...
C07D 231/12 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/4178 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/427 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61P 13/10 (2018.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 491/052 (2013.01);
Abstract

The present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which has TRPM8 inhibitory effects: wherein ring A is Caryl or the like; X is CRor the like; Rand Rare a hydrogen atom or the like; Ris a hydrogen atom or the like; Ris a hydrogen atom or the like; ring B is Caryl or the like; Ris a hydrogen atom or the like; Ris a hydrogen atom or the like; Ris a hydrogen atom or the like; Ris a hydrogen atom or the like; Ris a hydrogen atom or the like; Ris a hydrogen atom or the like; n is 0, 1 or 2. Therefore, the compound represented by the formula (I) of the present invention or a pharmaceutically acceptable salt thereof is useful as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.

Find Patent Forward Citations

Loading…